Show simple item record

dc.contributor.authorReyes Martín, Efraim
dc.contributor.authorPrieto Aretxabaleta, Liher ORCID
dc.contributor.authorMilelli, Andrea
dc.date.accessioned2023-01-12T14:44:47Z
dc.date.available2023-01-12T14:44:47Z
dc.date.issued2022-12-29
dc.identifier.citationMolecules 28(1) : (2023) // Article ID 271es_ES
dc.identifier.issn1420-3049
dc.identifier.urihttp://hdl.handle.net/10810/59261
dc.description.abstractMajority of drugs act by interacting with chiral counterparts, e.g., proteins, and we are, unfortunately, well-aware of how chirality can negatively impact the outcome of a therapeutic regime. The number of chiral, non-racemic drugs on the market is increasing, and it is becoming ever more important to prepare these compounds in a safe, economic, and environmentally sustainable fashion. Asymmetric organocatalysis has a long history, but it began its renaissance era only during the first years of the millennium. Since then, this field has reached an extraordinary level, as confirmed by the awarding of the 2021 Chemistry Nobel Prize. In the present review, we wish to highlight the application of organocatalysis in the synthesis of enantio-enriched molecules that may be of interest to the pharmaceutical industry and the medicinal chemistry community. We aim to discuss the different activation modes observed for organocatalysts, examining, for each of them, the generally accepted mechanisms and the most important and developed reactions, that may be useful to medicinal chemists. For each of these types of organocatalytic activations, select examples from academic and industrial applications will be disclosed during the synthesis of drugs and natural products.es_ES
dc.description.sponsorshipThe authors acknowledge the Spanish Agencia Estatal de Investigación (FEDER-PID2020-118422-GB-I00), the Basque Government (Grupos IT1558-22), and the University of Bologna for financial support.es_ES
dc.language.isoenges_ES
dc.publisherMDPIes_ES
dc.relationinfo:eu-repo/grantAgreement/MICINN/PID2020-118422-GB-I00es_ES
dc.rightsinfo:eu-repo/semantics/openAccesses_ES
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/
dc.subjectasymmetric organocatalysises_ES
dc.subjectchiralityes_ES
dc.subjectchiral drugses_ES
dc.subjectdrug discoveryes_ES
dc.subjectdrug synthesises_ES
dc.titleAsymmetric Organocatalysis: A Survival Guide to Medicinal Chemistses_ES
dc.typeinfo:eu-repo/semantics/articlees_ES
dc.date.updated2023-01-06T13:52:49Z
dc.rights.holder© 2022 by the authors.Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/ 4.0/).es_ES
dc.relation.publisherversionhttps://www.mdpi.com/1420-3049/28/1/271es_ES
dc.identifier.doi10.3390/molecules28010271
dc.departamentoesQuímica Orgánica e Inorgánica
dc.departamentoeuKimika Organikoa eta Ez-Organikoa


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record

© 2022 by the authors.Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/ 4.0/).
Except where otherwise noted, this item's license is described as © 2022 by the authors.Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/ 4.0/).